Efficacy and Safety of Ultrasound Cycloplasty for Refractory Glaucoma: A 3-Year Study

被引:12
|
作者
Rouland, Jean-Francois [1 ]
Aptel, Florent [2 ]
机构
[1] Claude Huriez Univ, Dept Ophthalmol, Lille, France
[2] Grenoble Alpes Univ Hosp, Dept Ophthalmol, Grenoble, France
关键词
refractory glaucoma; ultrasound cycloplasty procedure; cyclodestruction; DIODE-LASER CYCLOPHOTOCOAGULATION; TERM-FOLLOW-UP; DEVICE;
D O I
10.1097/IJG.0000000000001796
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Precis: Ultrasound cycloplasty (UCP) treatment using high-intensity focused ultrasound is an effective and safe therapy to reduce intraocular pressure (IOP) in patients with refractory glaucoma over a 3-year period. Purpose: The purpose of this study was to evaluate the 3-year efficacy and safety of UCP in patients with refractory glaucoma. Patients and Methods: In all, 104 patients with refractory glaucoma recruited from 2 university hospitals underwent UCP. Examinations were performed 7 days, 1 week, 1, 3, 6, 12, 24, and 36 months after the UCP procedure. Primary outcomes were therapeutic success at 3 years (IOP reduction from baseline >= 20% and IOP >5 mm Hg without other surgical procedures) and vision-threatening complications. Secondary outcomes included mean IOP change from baseline at each follow-up visit, medication use, complications, and subsequent UCP and/or other postsurgical interventions. Results: At 3 years post-UCP, the therapeutic success rate was 55%. For 75% of the patients, results were obtained with only one procedure. For the overall study population, IOP was reduced significantly (P<0.005) from 27.6 +/- 8.9 mm Hg (n=3.0 topical hypotensive medication) to 17.0 +/- 6.8 mm Hg at 36 months (n=2.8 topical hypotensive medication) (33% reduction). For the success patients, the IOP was initially 29.3 +/- 8.8 mm Hg (n=3.0 topical hypotensive medication) and 15.6 +/- 4.3 mm Hg at 36 months (n=2.8 topical hypotensive medication) (43% reduction). The rate of complications was low and there were no cases of phthisis. Conclusion: The UCP procedure was efficacious with few complications and should be considered as an alternative to other IOP-lowering therapies including laser cyclocoagulation in patients with refractory glaucoma.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 50 条
  • [41] Safety and efficacy of a low-cost glaucoma drainage device for refractory childhood glaucoma
    Kaushik, Sushmita
    Kataria, Pankaj
    Raj, Srishti
    Pandav, Surinder Singh
    Ram, Jagat
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (12) : 1623 - 1627
  • [42] Comparison of safety and efficacy between silicone and polypropyIene Ahmed glaucoma valves in refractory glaucoma
    Law, SK
    Nguyen, A
    Coleman, AL
    Caprioli, J
    OPHTHALMOLOGY, 2005, 112 (09) : 1514 - 1520
  • [43] 3-YEAR SAFETY AND EFFICACY DATA ON THE USE OF FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    STONER, E
    ANDRIOLE, GL
    BOAKE, R
    BRACKEN, BR
    BRANNAN, W
    FUSELIER, H
    BREMNER, W
    BRUSKEWITZ, RC
    COX, CE
    PATTERSON, AL
    CUNNINGHAM, GR
    DEVINE, PC
    SCHELLHAMMER, PF
    ELHILALI, M
    GELLER, J
    GRAYHACK, JT
    HARRISON, LH
    HUDSON, PB
    IMPERATO, J
    VAUGHAN, ED
    LIEBER, MM
    LIPPERT, MC
    MALEK, GH
    MCCONNELL, JD
    NARAYAN, P
    PERREAULT, JP
    RESNICK, MI
    NORMAN, R
    RITTMASTER, R
    ROMAS, NA
    ROSNER, W
    ROSENBLATT, S
    ROY, JB
    SEIDMON, EJ
    TENOVER, JS
    TRACHTENBERG, J
    WILLIAMS, RD
    WALSH, PC
    MOCELLINI, A
    GARDINER, R
    MARSHALL, V
    JOHNSON, W
    BARTSCH, G
    SCHMIDBAUER, CP
    MOSSIG, H
    GASSER, G
    VANCANGH, PJ
    DENIS, LJ
    ARAP, S
    FREIRE, GC
    UROLOGY, 1994, 43 (03) : 284 - 294
  • [44] ENDRALAZINE, A NEW PERIPHERAL VASODILATOR - EVALUATION OF SAFETY AND EFFICACY OVER A 3-YEAR PERIOD
    BOGERS, WAJL
    MEEMS, L
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (03) : 301 - 305
  • [45] Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases
    Arase, Yoshitaka
    Tsuruya, Kota
    Hirose, Shunji
    Ogiwara, Naoki
    Yokota, Masashi
    Anzai, Kazuya
    Deguchi, Ryuzo
    Shiraishi, Koichi
    Shirai, Takayuki
    Kagawa, Tatehiro
    HEPATOLOGY, 2020, 71 (02) : 757 - 759
  • [46] Pioglitazone vs Glyburide: safety results from a 3-year study
    Kupfer, S.
    Spanheimer, R.
    Perez, A.
    Khan, M.
    EUROPEAN HEART JOURNAL, 2006, 27 : 535 - 535
  • [47] Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
    Gane, Edward J.
    Wang, Yuming
    Liaw, Yun-Fan
    Hou, JinLin
    Thongsawat, Satawat
    Wan, MoBin
    Moon, Young M.
    Jia, JiDong
    Chao, You C.
    Niu, Junqi
    Leung, Nancy
    Samuel, Didier
    Hsu, Chao Wei
    Bao, Weibin
    Lopez, Patricia
    Avila, Claudio
    LIVER INTERNATIONAL, 2011, 31 (05) : 676 - 684
  • [48] EFFICACY AND SAFETY OF 3-YEAR DENOSUMAB THERAPY FOR OSTEOPOROSIS IN PATIENTS WITH AUTOIMMUNE LIVER DISEASES
    Arase, Yoshitaka
    Tsuruya, Kota
    Anzai, Kazuya
    Hirose, Shunji
    Shiraishi, Koichi
    Kagawa, Tatehiro
    HEPATOLOGY, 2019, 70 : 865A - 866A
  • [49] EFFICACY OF A PSYCHIATRIC HALFWAY HOUSE - 3-YEAR STUDY OF A THERAPEUTIC RESIDENCE
    GUMRUKCU, P
    SOCIOLOGICAL QUARTERLY, 1968, 9 (03): : 374 - 386
  • [50] ACETAZOLAMIDE (DIAMOX) THERAPY IN CHRONIC GLAUCOMA - A 3-YEAR FOLLOW-UP STUDY
    DECARVALHO, CA
    LAWRENCE, C
    STONE, HH
    ARCHIVES OF OPHTHALMOLOGY, 1958, 59 (06) : 840 - 849